Theres two things i can think of that haven't been mentioned yet. The first being:
"The capital expenditure component of the contract has proceeded as expected, however consumables offtake is expected to be behind approx. 2-3 months due to delays in the opening of the hospital which is now expected in May/June 2017."
And the second being:
"Admedus intends to provide an update on the progress of sales for these products during 2017 following launch into the US market."
Which implies neither vascucel nor cardiocel neo are selling in the states yet, which is news to me!
Ann: Appendix 4C - quarterly, page-31
-
- There are more pages in this discussion • 217 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.65 |
Change
-0.350(2.33%) |
Mkt cap ! $309.6M | |||
| Open | High | Low | Value | Volume |
| $14.50 | $14.94 | $14.25 | $1.266M | 86.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 126 | $14.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.65 | 99 | 1 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |